EUCTR2007-000744-28-IT进行中（未招募）不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX , in subjects equal or over 70 years of age - ND
Sanofi Pasteur MSD S.N.C.0 个研究点目标入组 750 人开始时间: 2007年11月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age ≥ 70 years
- •2.Varicella history-positive or residence for > 30 years in a country with endemic VZV infection
- •3.Signed informed consent form prior to any study procedure
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Febrile (oral temperature ≥ 38.3C) within the last 72 hours before the first vaccination
- •2.History of hypersensitivity/ anaphylactoid reaction to ZOSTAVAX components including gelatin or neomycin
- •3.Prior herpes-zoster episode clinically diagnosed by a physician
- •4.Prior receipt of varicella or zoster vaccine
- •5.Exposure to varicella or herpes-zoster within the 4 weeks prior to the first vaccination by continuous household contact, or non-household contact (generally >1 hour of exposure indoors), or hospital contact (in same 2- to 4-beds room or adjacent beds in a large ward or face-to-face contact with an infectious staff member or subject), or contact with a newborn whose mother had onset of varicella 5 days or less before delivery or within 48 hours after delivery
- •6.Significant underlying illness preventing completion of the vaccination schedules
- •7.Known active tuberculosis
- •8.Immune deficiency disorder, including active neoplastic disease (except local skin cancer) within the prior 5 years
- •9.Immune function impairment caused by medical condition (congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin?s disease, multiple myeloma, generalised malignancy), or immunosuppressive therapy (examples: chemotherapy agents to treat cancer, treatments associated with organ or bone marrow transplantation, daily (or on alternate days) systemic corticosteroids at a dose ≥5mg/day prednisone equivalent for at least 14 days in the 4 weeks prior to the first vaccination), or any other cause
- •10.Receipt of any inactivated vaccine within the 2 weeks prior to the first vaccination
- •11.Receipt of any other live vaccine within the 4 weeks prior to the first vaccination
- •12.Receipt of immunoglobulins or blood-derived products within the 5 months prior to the first vaccination
- •13.Concomitant use of non-topical antiviral therapy (examples: acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, cidofovir, brivudine)
- •14.History of alcohol or recreational drug abuse which in the opinion of the investigator could interfere with study compliance
- •15.Any other condition / situation that in the opinion of the investigator could interfere with the interpretation of the study, including possible interference caused by acute intercurrent illness (examples: upper respiratory infection, influenza), or any other cause
- •16.Participation to any other clinical study that includes an investigational product within the 4 weeks prior to the first vaccination or planned during the duration of the study
研究者
相似试验
已完成
3 期
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX, in subjects >= 70 years of ageShingles10047438Herpes ZosterNL-OMON31421Sanofi Pasteur MSD S.N.C.150
进行中（未招募）
不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of ageMeasles, mumps, rubella and varicella vaccine administered to healthy children from 9 months of ageEUCTR2007-002468-88-FISanofi Pasteur MSD SNC1,620
进行中（未招募）
1 期
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX ®, in subjects = 70 years of ageEUCTR2007-000744-28-NLSanofi Pasteur MSD S.N.C.
进行中（未招募）
不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of ageMeasles, mumps, rubella and varicella vaccine administered to healthy children from 9 months of ageEUCTR2007-002468-88-DESanofi Pasteur MSD SNC1,620
进行中（未招募）
不适用
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjugate (MCC) vaccine in healthy infantsRotaTeq® is indicated for the active immunisation of infants from age of 6 weeks for prevention of gastroenteritis due to rotavirus infection.NeisVac-C® is indicated for active immunisation of children from 2 months of age for the prevention of invasive disease caused by Neisseria meningitidis serogroup CEUCTR2006-005445-11-FISanofi Pasteur MSD S.N.C.